



Schweizerische Pädiatrische Onkologie Gruppe
Groupe d'Oncologie Pédiatrique Suisse
Gruppo d'Oncologia Pediatrica Svizzera
Swiss Paediatric Oncology Group

MNP2.0

Molecular neuropathology 2.0 – to increase the diagnostic accuracy of childhood brain tumours

The University clinic of Heidelberg and the Deutsche Krebsforschungszentrum in Germany are responsible for the international implementation of the study as sponsor. The Swiss Paediatric Oncology Group (SPOG) is responsible for performing the study in Switzerland (sponsor representative).

Background

One of the reasons why brain tumours cannot yet be treated optimally and cured in all patients may be the not entirely clear classification of these cancers into clinically and biologically different groups. Other than the very well-established neuropathological and neuroradiological reference assessment, there is in most cases no systematic molecular description of these tumours. MNP2.0 aims to pave the way for the widespread introduction of molecular diagnostics as the third pillar in the diagnosis of childhood brain cancers.

Why does the study need to be done?

The aim of the study is to describe the genetic information (DNA) in brain tumours with the aid of molecular analytical methods. This additional biological diagnostic procedure should reduce the rate of misdiagnosis and will permit subgroups to be identified that could be of great importance in taking therapy decisions.

Contact details for the sponsor representative in Switzerland:

Fundraising
SPOG Coordinating Center
Effingerstrasse 33
3008 Bern
Phone: +41 31 389 91 89